Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.55 |
| ▸ | KDM1A | O60341 | 5/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | CCKAR | P32238 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16640308 | 0.91 | KDM1A (0.51) | MGLLKDM1APTGS2PTGS1EPHX2 | |
| SCHEMBL16640297 | 0.89 | MGLL (0.57) | MGLLPTGS2CCKARPTGS1EPHX2 | |
| SCHEMBL16640299 | 0.79 | MALT1 (0.58) | MGLLKDM1APTGS2MALT1 | |
| SCHEMBL16640306 | 0.79 | PTGS2 (0.65) | MGLLKDM1APTGS2PTGS1EPHX2 | |
| SCHEMBL16640307 | 0.79 | RPA1 (0.56) | MGLLPTGS2CCKARMALT1ALDH1A1 | |
| SCHEMBL15004250 | 0.79 | MGLL (0.59) | MGLLKDM1APTGS2BRD4MALT1 | |
| SCHEMBL16640302 | 0.79 | PTGS2 (0.64) | MGLLPTGS2CCKARPTGS1EPHX2 | |
| SCHEMBL15004248 | 0.78 | MALT1 (0.57) | MGLLKDM1APTGS2MALT1 | |
| SCHEMBL16640298 | 0.78 | MALT1 (0.57) | MGLLKDM1APTGS2MALT1 | |
| SCHEMBL16640300 | 0.78 | RPA1 (0.55) | MGLLPTGS2CCKARMALT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105388-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105388-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105388-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | PAICS, AADAC, TPMT | MGLL 4358/4885KDM1A 1200/4885PTGS2 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.